128 related articles for article (PubMed ID: 21415217)
1. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
Kurtzberg LS; Roth S; Krumbholz R; Crawford J; Bormann C; Dunham S; Yao M; Rouleau C; Bagley RG; Yu XJ; Wang F; Schmid SM; Lavoie EJ; Teicher BA
Clin Cancer Res; 2011 May; 17(9):2777-87. PubMed ID: 21415217
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
[TBL] [Abstract][Full Text] [Related]
3. Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
Singh SK; Ruchelman AL; Li TK; Liu A; Liu LF; LaVoie EJ
J Med Chem; 2003 May; 46(11):2254-7. PubMed ID: 12747798
[TBL] [Abstract][Full Text] [Related]
4. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
6. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.
Houghton PJ; Lock R; Carol H; Morton CL; Gorlick R; Anders Kolb E; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups CA; Zhang MX; Madden SL; Teicher BA; Smith MA
Pediatr Blood Cancer; 2012 Feb; 58(2):200-9. PubMed ID: 21548007
[TBL] [Abstract][Full Text] [Related]
7. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
Sooryakumar D; Dexheimer TS; Teicher BA; Pommier Y
Mol Cancer Ther; 2011 Aug; 10(8):1490-9. PubMed ID: 21636699
[TBL] [Abstract][Full Text] [Related]
8. Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.
Feng W; Satyanarayana M; Tsai YC; Liu AA; Liu LF; Lavoie EJ
Bioorg Med Chem Lett; 2008 Jun; 18(12):3570-2. PubMed ID: 18511275
[TBL] [Abstract][Full Text] [Related]
9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
Bagley RG; Roth S; Kurtzberg LS; Rouleau C; Yao M; Crawford J; Krumbholz R; Lovett D; Schmid S; Teicher BA
Int J Oncol; 2009 May; 34(5):1329-40. PubMed ID: 19360345
[TBL] [Abstract][Full Text] [Related]
11. 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity.
Zhu S; Ruchelman AL; Zhou N; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 2006 May; 14(9):3131-43. PubMed ID: 16412652
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
13. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.
Yao L; Zhao X; Li Q; Zu Y; Fu Y; Zu B; Meng X; Liu C
Int J Pharm; 2012 Feb; 423(2):586-8. PubMed ID: 22193057
[TBL] [Abstract][Full Text] [Related]
15. Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity.
Ruchelman AL; Zhu S; Zhou N; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem Lett; 2004 Nov; 14(22):5585-9. PubMed ID: 15482929
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.
You QD; Li ZY; Huang CH; Yang Q; Wang XJ; Guo QL; Chen XG; He XG; Li TK; Chern JW
J Med Chem; 2009 Sep; 52(18):5649-61. PubMed ID: 19715319
[TBL] [Abstract][Full Text] [Related]
17. cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: synthesis and cytotoxicity in human cancer cell lines in vitro.
Desbois N; Pertuit D; Moretto J; Cachia C; Chauffert B; Bouyer F
Eur J Med Chem; 2013 Nov; 69():719-27. PubMed ID: 24095763
[TBL] [Abstract][Full Text] [Related]
18. Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: influence on topoisomerase I-targeting activity and cytotoxicity.
Ruchelman AL; Kerrigan JE; Li TK; Zhou N; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 2004 Jul; 12(13):3731-42. PubMed ID: 15186859
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Satyanarayana M; Feng W; Cheng L; Liu AA; Tsai YC; Liu LF; LaVoie EJ
Bioorg Med Chem; 2008 Aug; 16(16):7824-31. PubMed ID: 18676151
[TBL] [Abstract][Full Text] [Related]
20. A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors.
Miao Z; Zhu L; Dong G; Zhuang C; Wu Y; Wang S; Guo Z; Liu Y; Wu S; Zhu S; Fang K; Yao J; Li J; Sheng C; Zhang W
J Med Chem; 2013 Oct; 56(20):7902-10. PubMed ID: 24069881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
